Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)
Udelson, Lewis, Shah, Zile, Redfield, Burnett, Mittleman, Profy, Seferovic, Reasner, Konstam (2020) Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF) Am Heart J (IF: 4.8) 222 183-190Links
http://www.ncbi.nlm.nih.gov/pubmed/32105984http://dx.doi.org/10.1016/j.ahj.2020.01.009
